ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Falls 14.6% – Time to Sell?

ChronoScale Corporation Common Stock (NASDAQ:CHRN – Get Free Report) shares fell 14.6% during trading on Wednesday. The company traded as low as $8.18 and last traded at $8.32. 141,074 shares changed hands during trading, a decline of 36% from the average daily volume of 219,053 shares. The stock had previously closed at $9.74.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on CHRN shares. Northland Securities began coverage on ChronoScale Corporation Common Stock in a research report on Friday, September 18th. They issued an “outperform” rating and a $32.00 price target on the stock. Compass Point started coverage on ChronoScale Corporation Common Stock in a research report on Friday, October 16th. They set a “buy” rating and a $25.00 target price for the company. Finally, Weiss Ratings lowered shares of ChronoScale Corporation Common Stock from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, October 23rd. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $28.50.

Read Our Latest Stock Analysis on ChronoScale Corporation Common Stock

ChronoScale Corporation Common Stock Price Performance

The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -2.09 and a beta of 1.12. The company has a current ratio of 0.30, a quick ratio of 0.30 and a debt-to-equity ratio of 0.02. The company has a 50 day moving average of $16.39 and a 200 day moving average of $16.14.

ChronoScale Corporation Common Stock (NASDAQ:CHRN – Get Free Report) last posted its earnings results on Wednesday, October 14th. The company reported ($0.29) earnings per share (EPS) for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 66.16%. The business had revenue of $41.48 million during the quarter. Equities research analysts predict that ChronoScale Corporation Common Stock will post -0.49 EPS for the current fiscal year.

ChronoScale Corporation Common Stock Company Profile

(Get Free Report)

Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

See Also

Receive News & Ratings for ChronoScale Corporation Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChronoScale Corporation Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.